Business
JPMorgan Chase tops estimates as trading revenue hits a record of nearly $9 billion
JPMorgan Chase on Tuesday topped analysts’ estimates for the third quarter as trading and investment banking generated about $700 million more revenue than expected.
Here’s what the company reported:
- Earnings per share: $5.07 vs. expected $4.84, according to LSEG
- Revenue: $47.12 billion vs. expected $45.4 billion, according to LSEG
The bank said in a release that profit jumped 12% to $14.39 billion, or $5.07 per share, from a year earlier. Revenue rose 9% to $47.12 billion.
So far this year, the biggest American banks have benefited under the administration of President Donald Trump.
They’ve reaped higher trading revenue as upheaval from his policies has roiled markets around the world, forcing investors to reposition themselves. JPMorgan’s trading haul of $8.9 billion was a record for a third quarter, CEO Jamie Dimon said in the release.
Investment bankers are busier thanks to a more relaxed stance toward mergers, and Trump’s bank regulators have proposed ways to ease capital requirements and stress tests. Stock market indexes that are at or near record levels have helped the wealth management divisions of banks including JPMorgan.
Fixed income trading at JPMorgan jumped 21% in the quarter to $5.6 billion, about $300 million more than the StreetAccount estimate.
Equity trading surged 33% to $3.3 billion, also roughly $300 million more than expected.
Investment banking fees jumped 16% to $2.6 billion, edging out the $2.5 billion StreetAccount estimate.
Dimon said that while each of his major business lines performed well against a good economic backdrop, he was preparing the firm for possible turbulence ahead.
“While there have been some signs of a softening, particularly in job growth, the U.S. economy generally remained resilient,” Dimon said.
“However, there continues to be a heightened degree of uncertainty stemming from complex geopolitical conditions, tariffs and trade uncertainty, elevated asset prices and the risk of sticky inflation,” Dimon said. “As always, we hope for the best, but these complex forces reinforce why we prepare the firm for a wide range of scenarios.”
JPMorgan’s provision for credit losses rose 9% to $3.4 billion, exceeding the $3.08 billion estimate, indicating that the firm is preparing for higher loan defaults down the road.
Big banks have outperformed regional lenders so far this year; the KBW Bank Index has climbed nearly 15%, while the KBW Regional Banking Index has dropped roughly 1%.
Goldman Sachs, Citigroup and Wells Fargo also reported earnings Tuesday, with Bank of America and Morgan Stanley releasing results Wednesday.
This story is developing. Please check back for updates.

Business
Anthropic officially designated a supply chain risk by Pentagon
The supply chain risk designation of the artificial intelligence firm is a first for a US company.
Source link
Business
FDA official calls UniQure’s gene therapy a ‘failed’ treatment for Huntington’s disease
Thomas Fuller | SOPA Images | Lightrocket | Getty Images
UniQure needs to run another study to prove that its gene therapy “actually helps people with Huntington’s disease,” a senior U.S. Food and Drug Administration official said on a call with reporters Thursday.
The official, who requested anonymity before discussing sensitive information, confirmed the agency has asked the company to run a placebo controlled trial of its treatment, which is administered directly into the brain. UniQure has said that type of study isn’t ethical because it would require putting people under general anesthesia for hours, a characterization the official disputed.
“So what is really going on? UniQure is the latest company to make a failed therapy for Huntington’s patients,” the official said. “They likely acknowledge or understand at some deep level that their trial failed years ago, and instead of doing the right thing and running the correct clinical study, UniQure is performing a distorted or manipulated comparison in the mind of FDA.”
The comments mark the latest development in a messy public spat between UniQure and the FDA, and as the agency comes under fire for a number of recent drug approval application rejections, including some where companies have accused it of going back on previous guidance. FDA Commissioner Marty Makary in an interview with CNBC’s Becky Quick last week seemingly criticized UniQure’s gene therapy for Huntington’s disease. Makary didn’t name UniQure but described its treatment.
UniQure then accused the FDA of reversing its stance that the company’s clinical trial data would be sufficient to seek approval. UniQure’s study used an outside database to measure how patients with Huntington’s disease might decline without treatment, known as an external control. UniQure has said it wouldn’t be feasible to run a true randomized, double-blind placebo-controlled study, considered the gold standard, because it wouldn’t be ethical to make people undergo a sham hours-long brain surgery.
The FDA official said the agency “never agreed to accept this distorted comparison” and the FDA “never makes such assurances.” Instead, the “FDA will always say, ‘Well, we have to see the data when we get it.'”
UniQure didn’t immediately comment.
The company’s stock rose more than 10% on Thursday and has fallen 58% this year as of Thursday afternoon.
Business
US mortgage rates rise to 6% after three-week slide as oil-driven bond yields climb – The Times of India
The average long-term US mortgage rate edged higher this week, ending a three-week decline as bond yields rose amid oil-price pressures linked to the war with Iran.The benchmark 30-year fixed mortgage rate increased to 6% from 5.98% last week, mortgage buyer Freddie Mac said on Thursday. A year ago, the average rate stood at 6.63%, AP reported.The modest uptick breaks a three-week slide in borrowing costs, with mortgage rates having hovered close to the 6% mark for most of this year. Last week’s average had marked the first time the rate dipped below 6% since September 2022, reaching its lowest level in nearly three and a half years.Mortgage rates are influenced by several factors, including the Federal Reserve’s interest-rate policy, investor expectations about inflation and economic growth, and movements in the bond market.They typically track the direction of the 10-year US Treasury yield, which lenders use as a benchmark for pricing home loans.The 10-year Treasury yield rose to 4.14% at midday Thursday, up from around 4% a week earlier.Treasury yields have moved higher in recent days as rising oil prices added fresh inflation concerns, potentially complicating the Federal Reserve’s plans to cut interest rates.
-
Business1 week agoAttock Cement’s acquisition approved | The Express Tribune
-
Politics1 week agoWhat are Iran’s ballistic missile capabilities?
-
Business7 days agoIndia Us Trade Deal: Fresh look at India-US trade deal? May be ‘rebalanced’ if circumstances change, says Piyush Goyal – The Times of India
-
Politics1 week agoUS arrests ex-Air Force pilot for ‘training’ Chinese military
-
Fashion1 week agoPolicy easing drives Argentina’s garment import surge in 2025
-
Business6 days agoGreggs to reveal trading amid pressure from cost of living and weight loss drugs
-
Sports1 week agoSri Lanka’s Shanaka says constant criticism has affected players’ mental health
-
Sports6 days agoLPGA legend shares her feelings about US women’s Olympic wins: ‘Gets me really emotional’
